FDA Expands Rozlytrek Indication to Include Some Solid Tumors in Children at Least 1 Month Old

The Food and Drug Administration (FDA) approved an expanded indication for Rozlytrek (entrectinib) to include children older than one month with solid tumors that harbor the NTRK gene fusion without a known acquired resistance mutation, have metastatic disease or where surgical removal may result in severe morbidity and whose disease has progressed after treatment.

Read more: https://www.curetoday.com/view/fda-expands-rozlytrek-indication-to-include-some-solid-tumors-in-children-at-least-1-month-old